Gastric Cancer
Select Clinical Trial
Protocol Number: Amgen 20210096 (FORTITUDE-101)
Protocol Title: A randomized, double-blind, placebo-controlled phase 3 study of Bemarituzumab plus chemotherapy versus placebo plus chemotherapy in subjects with previously untreated advanced gastric or gastroesophageal junction cancer with FGFR2b Overexpression
Eligibility: Men and women age 18 and older with unresectable, locally advanced, or metastatic histologically documented gastric or GEJ adenocarcinoma.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: Amgen 20210098 (FORTITUDE-102)
Protocol Title: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma
Eligibility: Men and women age 18 and older with unresectable, locally advanced, or metastatic histologically documented gastric or GEJ adenocarcinoma with PDL-1 positive disease.
Contact Information: (910) 715-2200